Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by ImmunoGen, Inc. < Previous 1 2 Next > ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 01, 2024 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 03, 2024 From ImmunoGen, Inc. Via Business Wire Tickers IMGN FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer December 05, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 01, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference November 02, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer October 27, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 29, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 18, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer September 18, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 05, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan August 28, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 01, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer July 31, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results July 31, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference July 27, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates July 24, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 03, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 01, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference May 24, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares May 09, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting May 09, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Proposed Public Offering of Common Stock May 03, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 01, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results April 28, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer April 24, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors April 06, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 03, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting March 25, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 01, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN ImmunoGen Reports Recent Progress and 2022 Financial Results March 01, 2023 From ImmunoGen, Inc. Via Business Wire Tickers IMGN < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.